Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.
(angiotensin ii receptor antagonists)
35,791 results
  • [Retarding progression of chronic kidney disease]. [Review]
    Inn Med (Heidelb). 2023 Feb 01 [Online ahead of print]Saritas T, Floege J
  • Chronic kidney disease (CKD) affects about 10-15% of the German population with a steady increase. It is assumed that CKD will become the 5th most common cause of death worldwide in 2040. CKD is associated with high risk of mortality, morbidity, related in particular to cardiovascular disease, as well as high healthcare costs. Clinical strategies to manage CKD should encompass extensive life-styl…
  • Cardiorenal benefits of finerenone: protecting kidney and heart. [Review]
    Ann Med. 2023 Dec; 55(1):502-513.González-Juanatey JR, Górriz JL, … Facila L
  • Persons with diabetes and chronic kidney disease (CKD) have a high residual risk of developing cardiovascular (CV) complications despite treatment with renin-angiotensin system blockers and sodium-glucose cotransporter type 2 inhibitors. Overactivation of mineralocorticoid receptors plays a key role in the progression of renal and CV disease, mainly by promoting inflammation and fibrosis. Fineren…
  • [European guidelines on heart failure: pharmacotherapy]. [Review]
    Herz. 2023 Jan 25 [Online ahead of print]Grundmann S, von Zur Mühlen C
  • The new 2021 guidelines of the European Society of Cardiology (ESC) have broken with the old step by step treatment of heart failure and have fundamentally revised the strategy in the pharmacotherapy setting. For patients with heart failure and reduced ejection fraction ≤ 40%, the 4 substance groups angiotensin-converting enzyme (ACE) inhibitors/angiotensin receptor-neprilysin inhibitors (ARNI), …
  • Management of heart failure in patients with kidney disease - updates from the 2021 ESC guidelines. [Journal Article]
    Nephrol Dial Transplant. 2023 Jan 23 [Online ahead of print]Edwards NC, Price AM, … Birmingham Cardio-Renal Group
  • The wide overlap between the syndromes of chronic kidney disease and chronic heart failure means that familiarity with the 2021 European Society of Cardiology guidelines is of importance to nephrologists. The common risk factors for the two syndromes together with the adverse cardiac structural remodelling associated with chronic kidney disease means that many kidney disease patients are breathle…
  • [Mineralocorticoid receptor (MR)-associated mechanisms in diabetic kidney disease and clinical significance of MR antagonists]. [Review]
    Am J Nephrol. 2023 Jan 20 [Online ahead of print]Mende CW, Samarakoon R, Higgins PJ
  • CONCLUSIONS: Upregulation of the renin-angiotensin-aldosterone system is an important contributor to kidney disease progression, as highlighted by the results of trials evaluating angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with albuminuria. Increasing evidence suggests the existence of a multidirectional network that involves aldosterone, the mineralocorticoid receptor (MR), and the Ras-related C3 botulinum toxin substrate 1 (Rac1) as driving forces in the generation of reactive oxygen species and oxidative stress-induced injury in the initiation of interstitial nephritis and eventual fibrosis in chronic kidney disease and DKD. The MR is a key element of this triangle, as highlighted by the beneficial effect of MR antagonists in preventing or reducing aldosterone- or Rac1-related effects in basic science studies, and the improved patient outcomes observed in clinical studies.Aldosterone can promote kidney disease in diabetes via the MR and via MR-independent actions through Rac1. However, the MR remains a key element of this triangle, with clinical data supporting the use of MR antagonists in delaying the progression of kidney disease in diabetes.
  • Management of Heart Failure with Reduced Ejection Fraction. [Review]
    Curr Probl Cardiol. 2023 Jan 18 [Online ahead of print]Rashid AM, Khan MS, … Butler J
  • Heart failure with reduced ejection fraction (HFrEF) is a complex and progressive clinical condition characterized by dyspnea and functional impairment. HFrEF has a high burden of mortality and readmission rate making it one of the most significant public health challenges. Basic treatment strategies include diuretics for symptom relief and use of quadruple therapy (Angiotensin receptor blocker/n…
  • The Neurohormonal Overactivity Syndrome in Heart Failure. [Journal Article]
    Life (Basel). 2023 Jan 16; 13(1)Xanthopoulos A, Skoularigis J, Triposkiadis F
  • Heart failure (HF) is categorized arbitrarily based on the left ventricular ejection fraction (LVEF) in HF with reduced (HFrEF; LVEF < 40%), mildly reduced (HFmrEF; LVEF 40-49%), or preserved ejection fraction (HFpEF; LVEF ≥ 50%). In this opinion paper, based on (patho)physiological considerations, we contend that the neurohormonal overactivity syndrome (NOHS), which is present in all symptomatic…
  • AT1R blocker prevents mental stress induced retrograde blood flow in overweight/obese men. [Journal Article]
    Physiol Rep. 2023 01; 11(1):e15566.Rocha HNM, Teixeira GF, … Rocha NG
  • The main goal was to determine the impact of mental stress (MS) on blood flow regulation in overweight/obese men. Fourteen overweight/obese men (27 ± 7 years; 29.8 ± 2.6 kg/m2) participated in two randomized experimental sessions with oral administration of the AT1R blocker Olmesartan (40 mg; AT1RB) or placebo (PL). After 2 h, a 5-min acute MS session (Stroop Color Word Test) was administered. Bl…
  • Efficacy and Safety of Vericiguat for Treatment of Heart Failure: A Systematic Review. [Review]
    Curr Probl Cardiol. 2023 Jan 06 [Online ahead of print]Shaikh TG, Jawed S, … Asghar MS
  • Heart failure is a growing global health concern with high mortality and morbidity. Beta-blockers, mineralocorticoid receptor antagonists, and angiotensin-converting-enzyme inhibitors are the treatments of choice for worsening clinical symptoms. In early 2021, the FDA approved a new oral soluble guanylate cyclase stimulator, Vericiguat, for the treatment of chronic heart failure. To evaluate the …
New Search Next